Dianthus Therapeutics | MGTA - Gross Profit On Sales

Stock Price
56.01
Daily Change
2.90 5.46%
Monthly
10.91%
Yearly
159.31%
Q1 Forecast
48.02

Dianthus Therapeutics reported $396K in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Akebia Therapeutics USD 49.21M 13.25M Mar/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Avita Medical AUD 14.95M 1.18M Jun/2025
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Deva Holding AS TRY 1.32B 235.77M Sep/2023
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Moderna USD 226M 583M Dec/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Organon & Co USD 854M 3M Dec/2025
Pharma Mar EUR 33.36M 20.25M Sep/2025
Qiagen NV USD 325.27M 19.53M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 67.63M 15.62M Mar/2025
Viatris USD 1.15B 223.6M Dec/2025
Xeris Pharmaceuticals USD 63.38M 3.74M Sep/2025
Zz Pientze Pharmaceu CNY 296.13M 1.1B Jun/2025